Context Therapeutics Inc.
Context Therapeutics Inc. is a clinical-stage biotechnology company developing immunotherapy product candidates for cancer. Its pipeline includes CTIM-76, CT-95 and CT-202, and the company is currently focused on advancing these assets through preclinical work and early-stage clinical trials while seeking regulatory approval and future commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes CTIM-76, CT-95 and CT-202 being advanced through nonclinical and early clinical development.
Internal discovery, preclinical testing, clinical trial execution and regulatory preparation for pipeline assets.
In-licensed or acquired programs and related intellectual property, know-how and regulatory assets.
Customers
Context Therapeutics does not yet sell approved products; its current 'customers' are primarily clinical trial sites, investigators, CROs and manufacturing partners that support development. If its candidates are approved, the end buyers would be oncology physicians, hospitals and cancer treatment centers using the therapies for patients with solid tumors.
CROs, investigators and trial sites that execute preclinical studies and Phase 1 trials for CTIM-76, CT-95 and CT-202.
Contract manufacturers and suppliers that provide drug substance, drug product and clinical trial materials.
Hospitals, cancer centers and physicians that would prescribe approved therapies to patients with cancer.
Biotech licensors and collaborators that provide assets, IP or development rights to expand the pipeline.
Strategy
Context Therapeutics is prioritizing advancement of its lead pipeline assets through early clinical development while building the manufacturing, regulatory and IP foundation needed for later-stage trials. A second priority is financing: the company expects to fund operations through equity, debt, collaborations and licensing until product revenue, if any, is available.
Clinical proof-of-concept is the main value driver for a pre-revenue biotech company.
The company has no product revenue and needs capital to fund R&D and operations.
Clinical supply and eventual commercialization require scalable external manufacturing and regulatory execution.
Patent protection is central to exclusivity, partnering leverage and eventual commercial value.
Geography
The company is headquartered in the United States and its development and financing activities are centered there. Its CT-95 patent estate is being prosecuted or maintained across the United States, Europe, Canada, Australia, Japan and Taiwan, reflecting a global intellectual property footprint even though the business remains pre-revenue.
Risks
The company is highly exposed to clinical, financing and intellectual property risk because it has no approved products and depends on successful development outcomes. Regulatory delays, patent disputes, manufacturing constraints and the need for repeated capital raises could materially affect its ability to continue operations and advance the pipeline.
- Financing riskImpact: HighLikelihood: Medium
The company expects to need substantial additional capital and has no committed credit facility.
Exposure: Operations into 2027 depend on assumptions that may prove inaccurate.
- Intellectual property litigationImpact: HighLikelihood: Medium
Third parties may assert patent claims or challenge the company’s rights to use key technology.
Exposure: CTIM-76 and CT-95 are specifically exposed to third-party patent risk.
- Clinical development failureImpact: High
Pipeline value depends on successful preclinical and Phase 1 results for CTIM-76, CT-95 and CT-202.
Exposure: Any trial setback could delay or eliminate future commercialization.
- Regulatory delay riskImpact: MediumLikelihood: Medium
FDA and broader U.S. regulatory changes can slow approvals and increase compliance burden.
Exposure: Early-stage oncology programs require multiple regulatory milestones.
- Supply chain and tariff riskImpact: MediumLikelihood: Medium
Imported raw materials and clinical supplies may become more expensive or harder to source.
Exposure: Manufacturing scale-up and clinical supply continuity could be affected.
Accounting
Judgemental itemsMost operating cash is spent on preclinical studies, clinical trials and personnel, so timing of spend drives reported losses.
Impact: Quarterly results can fluctuate materially with trial activity and vendor accruals.
Costs owed to CROs, investigators and manufacturers are estimated before invoices are finalized.
Impact: Accrual changes can move operating expenses and liabilities.
Upfront payments for CT-202 and CT-95-related assets may require careful treatment depending on asset classification and future use.
Impact: Affects balance sheet assets, expense recognition and future impairment risk.
As a public development-stage company, equity awards are a key part of compensation.
Impact: Raises G&A and R&D expense without immediate cash outflow.
The company can defer adoption of certain new accounting standards, affecting comparability with larger peers.
Impact: Financial statements may not be directly comparable to non-EGC biotech companies.
Similar listed companies
Publicly listed companies with a comparable business focus.
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Perspective Therapeutics, Inc.
CATX · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Bicycle Therapeutics plc
BCYC · Pharmaceutical Preparations
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company built around its proprietary Bicycle platform, which is used to design short synthetic…
BioAtla, Inc.
BCAB · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026